J. Zijlstra

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Josée M Zijlstra, Josee M. Zijlstra, Jose Zijlstra, Josée. M. Zijlstra, J M Zijlstra, J. M. Zijlstra, Josée Zijlstra, J Zijlstra, Josée M. Zijlstra, Josee Zijlstra, J.m. Zijlstra, Josee M Zijlstra, Joseé M Zijlstra, J. Zijlstra, Jose M. Zijlstra
Publication record
305 papers · 14,890 citations · H-index 50

PAPERS

A Lesion-adaptive Segmentation Approach for Tumor Delineation on FDG PET/CT in Diffuse Large B-cell Lymphoma Patients.
20260 citationsauthor #11
Segmentation method comparison for baseline [18F]FDG PET-CT in follicular lymphoma patients.
20260 citationsauthor #11
Circulating extracellular vesicle isomiR signatures predict therapy response in patients with multiple myeloma
20251 citationsauthor #13
89Zr-mAb uptake interpretation requires the use of tissue to plasma ratios corrected for antibody catabolism
20251 citationsauthor #6
Measuring Total Metabolic Tumor Volume from 18F-FDG PET: A Reality Check
202510 citationsauthor #20
Summary Report of the SNMMI AI Task Force Radiomics Challenge 2024
20250 citationsauthor #9
Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response
20250 citationsauthor #17
Improving the predictive value of end-of-treatment PET/CT in diffuse large B-cell lymphoma.
20250 citationsauthor #20
Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
20254 citationsauthor #4
[18F]FDG PET/CT: EANM procedure guidelines for tumour imaging: version 3.0
20255 citationsauthor #11
Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.
20250 citationsauthor #27
Predicting 2-year time to progression in diffuse large B cell lymphoma using 3D CNNs on whole-body PET/CT scans
20250 citationsauthor #18
Can we obtain prognostic information from healthy tissue uptake and volume in baseline 18F-FDG PET/CT imaging in diffuse large B-cell lymphoma?
20251 citationsauthor #6
Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma
20256 citationsauthor #23
Validating image-derived input functions of dynamic 18F-FDG long axial field-of-view PET/CT studies
20252 citationsauthor #8
Is FDG Metabolic Tumor Volume in lymphoma really happening?
202414 citationsauthor #3
Feasibility of Using 18F-FDG PET/CT Radiomics and Machine Learning to Detect Drug-Induced Interstitial Lung Disease
20242 citationsauthor #6
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma
20243 citationsauthor #7
Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial
20241 citationsauthor #3
Validation of an Artificial Intelligence–Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma
202411 citationsauthor #19
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
20248 citationsauthor #14
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.
20246 citationsauthor #13
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies.
20247 citationsauthor #36
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
202446 citationsauthor #15
Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET
20247 citationsauthor #6
Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Long-term results of the HOVON-84 randomized phase III study by the HOVON and the Nordic Lymphoma Group (clinical trial number: NTR1014).
20241 citationsauthor #5
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.
202465 citationsauthor #16
Towards IVDR‐compliance by implementing quality control steps in a quantitative extracellular vesicle‐miRNA liquid biopsy assay for response monitoring in patients with classic Hodgkin lymphoma
20244 citationsauthor #10
Full-length tRNAs lacking a functional CCA tail are selectively sorted into the lumen of extracellular vesicles
20241 citationsauthor #9
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study
202312 citationsauthor #12
Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial
20233 citationsauthor #7
Differences in baseline PET/CT lymphoma distribution patterns between DLBCL‐NOS and high‐risk DLBCL patients
20230 citationsauthor #9
P1139: COMPARISON OF 6XR-CHOP21 VERSUS 6XR-CHOP+2R FOR ADVANCED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA: A PROPENSITY SCORE WEIGHTED POPULATION-BASED ANALYSIS
20230 citationsauthor #7
Sensitivity of an AI method for [18F]FDG PET/CT outcome prediction of diffuse large B-cell lymphoma patients to image reconstruction protocols
20233 citationsauthor #10
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
202315 citationsauthor #10
Characterizing the Bone Marrow Environment in Advanced-Stage Myelofibrosis during Ruxolitinib Treatment Using PET/CT and MRI: A Pilot Study
20236 citationsauthor #10
An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients
202326 citationsauthor #33
Incomplete patient information exchange and unnecessary repeat diagnostics during oncological referrals in the Netherlands: exploring the role of information exchange
20232 citationsauthor #14
Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial
202310 citationsauthor #15
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.
202311 citationsauthor #8
Improved Risk Prediction in DLBCL By Combining Clinical and PET Features with Interim PET Assessment
20230 citationsauthor #17
Case report: XMEN disease: a patient with recurrent Hodgkin lymphoma and immune thrombocytopenia
20231 citationsauthor #8
Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 study
20230 citationsauthor #11
DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial
20230 citationsauthor #24
Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma
20238 citationsauthor #12
Important Role for Glutamine in Human and Mouse TME Models of CLL ; Towards Development of a PET Tracer As a Novel Diagnostic Tool
20230 citationsauthor #12
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
202344 citationsauthor #21
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
202314 citationsauthor #14
No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study
20231 citationsauthor #9
Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group
20231 citationsauthor #14
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours.
202317 citationsauthor #28
BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL
202321 citationsauthor #15
P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
20230 citationsauthor #24
P1159: INFERIOR OUTCOME OF FRAIL AND UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ATTENUATED R-CHOP
20230 citationsauthor #11
Cost-Utility of the eHealth Application ‘Oncokompas’, Supporting Incurably Ill Cancer Patients to Self-Manage Their Cancer-Related Symptoms: Results of a Randomized Controlled Trial
20228 citationsauthor #5
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
20226 citationsauthor #14
Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen
20223 citationsauthor #13
External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL
20222 citationsauthor #21
Detection and localization of early- and late-stage cancers using platelet RNA.
202291 citationsauthor #69
P071: First results of cardiovascular screening in a survivorship care program for Hodgkin lymphoma survivors in the Netherlands
20220 citationsauthor #3
Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018
202219 citationsauthor #9
Noise sensitivity of 89Zr-Immuno-PET radiomics based on count-reduced clinical images
20225 citationsauthor #5
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index
2022106 citationsauthor #15
Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
20220 citationsauthor #35
External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients
202251 citationsauthor #4
Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment
20221 citationsauthor #17
Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma
20221 citationsauthor #5
T064: Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors
20220 citationsauthor #11
Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion
20220 citationsauthor #17
The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma
202242 citationsauthor #11
Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
202211 citationsauthor #14
The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma
20220 citationsauthor #13
P070: Design of the INSIGHT study, evaluation of long-term follow-up care for lymphoma survivors in the Netherlands: does survivorship care at the BETER clinics reduce morbidity and mortality from late effects of lymphoma treatment and associated costs?
20220 citationsauthor #4
T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
20223 citationsauthor #15
Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features
202238 citationsauthor #10
Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma
20227 citationsauthor #7
Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
202215 citationsauthor #6
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
202215 citationsauthor #19
Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor
202228 citationsauthor #9
OS03.6.A Rituximab in primary CNS lymphoma - long term follow-up of the phase III HOVON 105/ALLG NHL 24 Study
20220 citationsauthor #10
Safety and Efficacy of Tinostamustine in Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL): Early Results from an Additional Expansion Cohort of a Phase I Study
20224 citationsauthor #7
Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma
20221 citationsauthor #7
P080: The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment
20220 citationsauthor #15
SEMI-AUTOMATED AI BASED ORGAN DELINEATION ON LOW DOSE CT TO FACILITATE PET RADIOTRACER BIODISTRIBUTION MEASUREMENTS
20222 citationsauthor #7
Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods
202217 citationsauthor #7
P073: Increased risk of colorectal cancer following treatment for Hodgkin lymphoma
20220 citationsauthor #12
T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
20222 citationsauthor #6
OC-0295 Colorectal cancer risk following radiotherapy and procarbazine for Hodgkin lymphoma
20220 citationsauthor #11
P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
20220 citationsauthor #14
Efficacy of the eHealth application Oncokompas, facilitating incurably ill cancer patients to self-manage their palliative care needs: A randomized controlled trial
202220 citationsauthor #5
Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma
20220 citationsauthor #20
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
20224 citationsauthor #1
Blood‐circulating EV‐miRNAs, serum TARC, and quantitative FDG‐PET features in classical Hodgkin lymphoma
20229 citationsauthor #13
High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial
20211 citationsauthor #14
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
202140 citationsauthor #8
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
202113 citationsauthor #2
PCR-free shallow whole genome sequencing for chromosomal copy number detection from plasma of cancer patients is an efficient alternative to the conventional PCR-based approach.
20219 citationsauthor #9
A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies
2021254 citationsauthor #4
Convolutional neural networks for automatic image quality control and EARL compliance of PET images
20216 citationsauthor #5
Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma
202112 citationsauthor #11

TIMELINE

2002 5 citations

2003 55 citations

2005 5 citations

2006 567 citations

2007 1,530 citations

2008 667 citations

2009 1,705 citations

2010 101 citations

2011 16 citations

2012 1,575 citations

2013 262 citations

2014 2,958 citations

2015 731 citations

2016 446 citations

2017 521 citations

2018 326 citations

2019 872 citations

2020 780 citations

2021 890 citations

2022 511 citations

2023 195 citations

2024 176 citations

2025 30 citations

2026 0 citations

Unknown 0 citations

J. Zijlstra

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT